Zhong et al., in their study using the DBA/2J mouse model of glaucoma, found no RGC loss up to 12 months of age of the mice treated with an intraperitoneal injection of various doses of EPO (3000, 6000, and 12,000 U/kg/week) compared to a 70% of total RGC loss in untreated control mice. This evidence concerns the gene EPO and glaucoma.